Amundi Boosts Position in Cencora, Inc. $COR

Amundi boosted its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 9.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,470,536 shares of the company's stock after purchasing an additional 131,826 shares during the quarter. Amundi owned approximately 0.76% of Cencora worth $425,514,000 at the end of the most recent reporting period.

• Top 3 S&P 500 Winners in a Losing Market

A number of other institutional investors also recently bought and sold shares of the company. Net Worth Advisory Group boosted its position in Cencora by 1.4% during the first quarter. Net Worth Advisory Group now owns 2,645 shares of the company's stock worth $736,000 after purchasing an additional 36 shares in the last quarter. Obermeyer Wealth Partners boosted its position in Cencora by 1.3% during the first quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company's stock worth $758,000 after purchasing an additional 36 shares in the last quarter. Cromwell Holdings LLC boosted its position in Cencora by 9.5% during the first quarter. Cromwell Holdings LLC now owns 450 shares of the company's stock worth $125,000 after purchasing an additional 39 shares in the last quarter. Pinnacle Wealth Management Advisory Group LLC raised its holdings in shares of Cencora by 2.7% in the first quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,565 shares of the company's stock worth $435,000 after acquiring an additional 41 shares during the last quarter. Finally, Private Trust Co. NA raised its holdings in shares of Cencora by 2.5% in the first quarter. Private Trust Co. NA now owns 1,933 shares of the company's stock worth $538,000 after acquiring an additional 47 shares during the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on COR shares. Robert W. Baird boosted their price target on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Citigroup boosted their price target on Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Wells Fargo & Company boosted their price target on Cencora from $337.00 to $354.00 and gave the stock an "overweight" rating in a report on Wednesday, August 13th. Jefferies Financial Group boosted their price target on Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a report on Monday, June 30th. Finally, Morgan Stanley set a $330.00 price target on Cencora and gave the stock an "equal weight" rating in a report on Wednesday, July 16th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Cencora currently has an average rating of "Moderate Buy" and a consensus target price of $311.25.

• Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy

View Our Latest Analysis on COR

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 4,968 shares of the firm's stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $294.11, for a total value of $1,461,138.48. Following the sale, the chief executive officer directly owned 42,351 shares in the company, valued at $12,455,852.61. This trade represents a 10.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $292.67, for a total value of $4,266,543.26. Following the transaction, the chairman owned 309,913 shares in the company, valued at approximately $90,702,237.71. This trade represents a 4.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,125 shares of company stock worth $9,993,789 over the last quarter. Insiders own 10.80% of the company's stock.

Cencora Price Performance

• Teva Pharma is the way to play the re-rise of generic drugs

COR stock opened at $294.82 on Thursday. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. Cencora, Inc. has a 1 year low of $218.65 and a 1 year high of $309.35. The firm has a market cap of $57.16 billion, a P/E ratio of 30.33, a price-to-earnings-growth ratio of 1.38 and a beta of 0.62. The stock has a 50-day simple moving average of $293.06 and a 200-day simple moving average of $282.92.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business had revenue of $80.66 billion during the quarter, compared to analyst estimates of $80.34 billion. During the same quarter last year, the firm earned $3.34 earnings per share. The company's revenue for the quarter was up 8.7% compared to the same quarter last year. On average, equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, August 15th. Cencora's dividend payout ratio is presently 22.63%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Read More

• Five stocks we like better than Cencora
• When to Sell a Stock for Profit or Loss
• Back-to-School Shopping Hits $40B: 3 Retail Stocks to Watch Now
• Are Penny Stocks a Good Fit for Your Portfolio?
• Alphabet Stock Surges After Dodging Harsh Antitrust Remedies
• 3 Healthcare Dividend Stocks to Buy
• Why Qualcomm Is Outperforming NVIDIA After Months of Lagging

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cencora Right Now?

Before you consider Cencora, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.

While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here